Research programme: antiviral therapeutics - H&P Labs

Drug Profile

Research programme: antiviral therapeutics - H&P Labs

Alternative Names: DEF-201; EboV inhibitors - H&P Labs

Latest Information Update: 24 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Brigham and Women's Hospital; Defyrus; Harvard University
  • Developer Brigham and Women's Hospital; Defyrus; H&P Labs; Harvard University
  • Class Adamantanes; Benzyl compounds; Interferons; Small molecules
  • Mechanism of Action Interferon alpha stimulants; Viral envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Viral infections
  • Research Ebola virus infections

Most Recent Events

  • 11 May 2015 H&P Labs secures $US350 000 from the National Research Council of Canada Industrial Research Assistance Program to finance development of antivirals
  • 08 Jan 2015 H&P Labs in-licenses Ebola virus inhibitors from Harvard University and Brigham and Women's Hospital
  • 08 Jan 2015 Early research in Ebola virus infections in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top